Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Furqan Ahmad Saddique, Muniba Farhad, Sana Aslam & Matloob Ahmad. (2021) Recent synthetic methodologies for the tricyclic fused-quinoline derivatives. Synthetic Communications 51:1, pages 13-36.
Read now
Read now
Articles from other publishers (13)
Pethaperumal Iniyavan, Anusha Avadhani, Yogendra Kumar, Arkalagud Satyanarayana Jeevan Chakravarthy, Mary Antony Palluruthiyil & Hiriyakkanavar Ila. (2022)
Synthesis of novel
9‐amino
/aryl/oxo‐2‐(het)arylthiazolo[4,5‐
b
]quinolines via palladium catalyzed
N
‐arylation
‐cyclization protocol
. Journal of Heterocyclic Chemistry.
Crossref
Crossref
Bin Zhang, Ting Zhang, Tian-Yi Zhang, Ning Wang, Shan He, Bin Wu & Hai-Xiao Jin. (2020) A Novel Methoxybenzyl 5-Nitroacridone Derivative Effectively Triggers G1 Cell Cycle Arrest in Chronic Myelogenous Leukemia K562 Cells by Inhibiting CDK4/6-Mediated Phosphorylation of Rb. International Journal of Molecular Sciences 21:14, pages 5077.
Crossref
Crossref
Katarzyna Nowak. (2014) A solvatochromic study of N-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide hydrochloride: An experimental and theoretical approach. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 130, pages 208-213.
Crossref
Crossref
Marco A. Loza-Mejía, Susana Olvera-Vázquez, Karina Maldonado-Hernández, Teresita Guadarrama-Salgado, Ignacio González-Sánchez, Fernando Rodríguez-Hernández, José D. Solano, Rogelio Rodríguez-Sotres & Alfonso Lira-Rocha. (2009) Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structure–activity relationship of 9-anilinothiazolo[5,4-b]quinoline derivatives. Bioorganic & Medicinal Chemistry 17:9, pages 3266-3277.
Crossref
Crossref
Carmen Avendaño & J. Carlos Menéndez. 2008. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs
199
228
.
Janusz Blasiak, Ewa Gloc, Jozef Drzewoski, Katarzyna Wozniak, Marek Zadrozny, Tomasz Skórski & Tomasz Pertynski. (2003) Free radical scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 535:1, pages 25-34.
Crossref
Crossref
F Caponigro, C Dittrich, J.B Sorensen, J.H.M Schellens, F Duffaud, L Paz Ares, D Lacombe, C de Balincourt & P Fumoleau. (2002) Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. European Journal of Cancer 38:1, pages 70-74.
Crossref
Crossref
Bruce C. Baguley, Kevin O. Hicks & William R. Wilson. 2002. Anticancer Drug Development. Anticancer Drug Development
269
cp1
.
Bruce C. Baguley. 2002. Anticancer Drug Development. Anticancer Drug Development
1
11
.
Lynnette R. Ferguson & Bruce C. Baguley. (1996) Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 355:1-2, pages 91-101.
Crossref
Crossref
G.J. Finlay, J.-F. Riou & B.C. Baguley. (1996) From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): Selectivity for topoisomerases I and II among acridine derivatives. European Journal of Cancer 32:4, pages 708-714.
Crossref
Crossref
Lynnette R. Ferguson, Glenn Whiteside, Karen M. Holdaway & Bruce C. Baguley. (1996) Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine. Environmental and Molecular Mutagenesis 27:4, pages 255-262.
Crossref
Crossref
Yoshihisa Iwamoto, Lynnette R. Ferguson, Amira Pearson & Bruce C. Baguley. (1992) Photo-enhancement of the mutagenicity of 9-anilinoacridine derivatives related to the antitumour agent amsacrine. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 268:1, pages 35-41.
Crossref
Crossref